Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial

Abstract

The aim of the study was to compare the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation (PE). In a single-blind placebo-controlled clinical study, 150 PE patients without erectile dysfunction (ED) were included during the period of March 2015 to May 2016. Patients were randomly divided into five groups (30 patients each). On demand placebo, paroxetine (30 mg), dapoxetine (30 mg), sildenafil citrate (50 mg) and combined dapoxetine (30 mg) with sildenafil citrate (50 mg) were given for patients for 6 weeks in each group respectively. All patients were instructed to record intravaginal ejaculatory latency time (IELT) and evaluated with Premature Ejaculation Diagnostic Tool (PEDT) and the patient satisfaction score before and after treatment. The mean of IELT, satisfaction score and PEDT in all groups was significantly improved after treatment (p value = .001). Combined dapoxetine with sildenafil group had the best values of IELT, satisfaction scores and PEDT in comparison with other treatment groups (p value <.001). The combined dapoxetine with sildenafil therapy could significantly improve PE patients without ED as compared to paroxetine alone or dapoxetine alone or sildenafil alone with tolerated adverse effects.

Changes in sexual performance and biochemical characterisation of functional neural regions: A study in serotonin transporter knockout male rats

“…Other researchers also found the SERT −/− rats differed from wild‐type rats in sexual behaviours (Chan et al, ; Joeyen‐Waldorf, Edgar, & Sibille, ; Olivier et al, ). Hence, the knockout animal model is highly useful for studying sexual performance, and the SERT protein is of great interest to many researchers as it is the target of SSRIs, which have been confirmed helpful to treat ejaculation dysfunction (Abu‐El‐Hamd & Abdelhamed, ).…”

Contractile Effects of Serotonin (5-HT) in the Rat Cauda Epididymis: Expression and Functional Characterization of 5-HT Receptors

“…This may indicate the existence of region-and cell-specific mechanisms for 5-HT removal in the epididymis. It is worthwhile to establish the mechanisms of 5-HT removal in the epididymis in vivo considering both adverse and therapeutic effects of SSRIs on sperm parameters as well as on ejaculatory function (Giuliano and Clément, 2005;Kendirci et al, 2007;Rowland et al, 2010;Tanrikut et al, 2010;Abu El-Hamd and Abdelhamed, 2018).…”

“…In men, high blood 5-HT levels were associated with poor sperm count and motility (Gonzales et al, 1992), and treatment with the antidepressant paroxetine, a selective serotonin reuptake inhibitor (SSRI), caused ejaculatory difficulties and increased sperm DNA fragmentation (Tanrikut et al, 2010). Despite these negative outcomes, SSRIs, such as dapoxetine, can be used in the pharmacotherapy of premature ejaculation (Giuliano and Clément, 2005;Rowland et al, 2010;Abu El-Hamd and Abdelhamed, 2018). It is thought that the effects of SSRIs on the regulation of ejaculatory function are mediated by increasing 5-HT signaling in the central nervous system.…”

Oral dapoxetine versus topical lidocaine as on‐demand treatment for lifelong premature ejaculation: A randomised controlled trial

“…In their meta‐analysis, JianWei, Ye, Li, and Wang (2018) reported an overall success rate of 30 mg and 60 mg oral dapoxetine of 24.2% and 38.5% respectively with no withdrawal symptoms after its stoppage. The common side effects reported with dapoxetine were nausea, headache and dizziness (Abu El‐Hamd & Abdelhamed, 2018).…”